Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?

2025-04-25 09:15:51 ET

Summary

• Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet.
• Biogen's Multiple Sclerosis treatments face patent expirations and competition, pressuring revenue; new Alzheimer's Disease and rare disease treatments could drive future growth.
• Financially, Biogen remains profitable with strong FCF, but reduced R&D spending and lack of insider buying or share buybacks are concerning.
• I rate BIIB stock a hold due to current uncertainties; will reconsider upon sustained revenue growth, regulatory approvals, or positive trial data.

Thesis

Biogen Inc. ( BIIB ) is a solid profit-generating company that has seen significant declines in its earnings and share price over the past few years, particularly due to declining revenue from their legacy Multiple Sclerosis treatments. Their recently approved drugs in areas such as Alzheimer’s Disease, alongside their pipeline expansion across rare diseases, immunology and in biosimilars, however, shows promise. Their turnaround plan also includes various cost savings to reduce operating expenses, yet shareholders have not been well rewarded over the past decade. A fresh round of share buybacks, and some insider buying, would send a clear message to shareholders, but without signs of either, and with new revenue streams not yet offsetting legacy revenue declines, the share price could be further pressured going forward....

Read the full article on Seeking Alpha

For further details see: